쎌바이오텍

049960KOSDAQ기초 의약물질 제조업

75.0 / 100

Reference Date: 2026-04-13

Financial Score31.5 / 40

News Sentiment18.5 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Rose 5.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Sebaitech operates in three main areas: probiotics, microbiome, and anti-cancer drug development. It maintains the top position in South Korea's probiotic exports and is developing functional foods for atopic dermatitis and menopausal symptoms through its microbiome business. The company also aims to create probiotic-based therapies for ulcerative colitis and colorectal cancer.

Number of Employees

123people

Average Salary

45.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.22Industry Average 33.458.0Point

Half of industry avg (excellent)

PBR

1.08Industry Average 2.035.5Point

Lower than industry avg (good)

ROE

7.92Industry Average -4.293.5Point

Well below industry avg

Debt Ratio

0.06Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼0.4% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲113.0% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 8.8% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 3Neutral 0Negative 0Average Sentiment Score 90

Positive
유산균 종주국 덴마크 시장도 잡은 K유산균...듀오락, 점유율 1위 달...
쎌바이오텍의 듀오락이 유산균 종주국 덴마크 시장에서 점유율 1위를 기록하며 K-유산균의 글로벌 경쟁력을 입증했습니다.
Positive
[바이오스냅] 듀오락, '유산균 종주국' 덴마크 시장서 1위 달성
쎌바이오텍의 듀오락이 덴마크 헬스케어 시장 조사기관 DLIMI 자료에서 덴마크 약국 시장 점유율 46.6%로 1위를 달성했습니다.
Positive
“이제 K-유산균 시대”…쎌바이오텍 ‘듀오락’, 종주국 덴마크서 점....
쎌바이오텍의 듀오락이 현지 브랜드를 제치고 덴마크 유산균 시장에서 점유율 1위에 오르며 K-유산균의 기술 경쟁력을 입증했습니다.

Detailed Momentum

52-week position8.0Point

Near 52w high (92%, uptrend)

Current 15,120Won52-week high 15,42052-week low 11,500

1-month return4.0Point

1m +5.00% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업가치제고계획(자율공시)2026-03-27
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18
Neutral감사보고서제출2026-03-18